Sunday, November 22, 2026
RSS

Tech

Amazon's Reported $7.5 Billion Decart Deal Tests Its AI Spending Strategy

Amazon's reported $7.5 billion Decart deal could test whether mega-cap AI spending remains durable during an AI-sector sell-off.

November 22, 2026
Tech
Tech
Trade with the conviction of the 1%.

Institutional-grade market intelligence delivered before the opening bell.

By subscribing, I agree to receive marketing emails and alerts. View our Privacy Policy. You may unsubscribe at any time.


Pharmaceutical

Oruka Therapeutics Insider Sale Puts Clinical-Stage Biotech Sentiment Under the Microscope

Oruka’s $853,985 insider sale draws attention as traders weigh the transaction against positive EVER…

Nov 21, 2026
Pharmaceutical

Viatris Wins FDA Approval for Neurontin Supplement as Legacy Franchise Remains in Focus

Viatris’ Neurontin supplemental submission SUPPL-60 received FDA approval, highlighting regulatory p…

Nov 21, 2026
Pharmaceutical

PMV Pharma Shares in Focus After Rezatapopt Data Sets Up Q1 2027 FDA Filing

PMV’s updated rezatapopt data show a 36% response rate across 168 evaluable patients, with a potenti…

Nov 21, 2026
Pharmaceutical

PMV Pharmaceuticals’ Updated Rezatapopt Data Puts Precision Oncology Back in Focus

PMV Pharmaceuticals’ updated PYNNACLE Phase 2 data gives investors a closer look at rezatapopt and i…

Nov 20, 2026
Pharmaceutical

Revolution Medicines Defies Market Selloff as Survival Data Lift RVMD

RVMD traded higher as survival data, a $226 William Blair target and new Phase 3 treatment activity …

Nov 20, 2026
Pharmaceutical

Belite Bio Slides 12% as FDA Extends Tinlarebant Review

Belite Bio shares fell 12% after the FDA extended its tinlarebant review by three months, resetting …

Nov 20, 2026
Pharmaceutical

Savara Shares Slip After FDA Delays Autoimmune PAP Decision

Savara’s missed FDA target date leaves investors facing a longer wait for clarity on its autoimmune …

Nov 20, 2026
Pharmaceutical

Revolution Medicines Rallies on Clinical Data as Biotech Decouples From Weak Market

Revolution Medicines showed premarket relative strength as clinical data offset a 1.0% S&P 500 decli…

Nov 20, 2026
Pharmaceutical

Capricor Therapeutics Defies Market Selloff as Traders Position for FDA Catalyst

CAPR rallied in premarket trading as the Nasdaq and S&P 500 declined, putting the biotech’s FDA cata…

Nov 20, 2026